cyrilzakka/clinical-trials huggingface dataset:
Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.

Eligibility Criteria:
Inclusion Criteria:

* Histopathological confirmation of malignant pleural mesothelioma .
* Full clinical data.
* Availability for follow up: Personal communication will be attempted in order to collect missing information.

  3-The files of all patients will be reviewed to analyze the following :
* Operative data if done .
* Pathological review and immunohistochemistry.
* Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test)
* Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\\S and MRI ).
* Treatment protocols applied: Radiotherapy and Chemotherapy.
* Response and survival after treatment .

Exclusion Criteria:

* cases not receive chemotherapy ,on available of evaluation after treatment
GATE: Generalized Anxiety - A Treatment Evaluation

The purpose of this randomized study is to examine the comparative efficacy of yoga, cognitive behavioral therapy, and stress education, a previously employed control condition, for patients with Generalized Anxiety Disorder.

We are currently conducting a treatment study to reduce stress and anxiety in people with generalized anxiety disorder (GAD). This study will not use a medication, but instead will involve weekly stress reduction classes that use different strategies to reduce anxiety. The study involves having a formal psychiatric interview, filling out questionnaires, ECGs, saliva samples, a urine test for drugs of abuse, and study visits over 12 weeks. Each study visit will take a few hours. Qualified participants will be compensated for time and travel.

Eligibility Criteria:
Inclusion Criteria:

* Male or female outpatients \> 18 years of age with a primary psychiatric diagnosis of generalized anxiety disorder
* Clinical Global Impression-Severity scale (CGI-S) score of 4 or higher
* Off concurrent psychotropic medication for at least 2 weeks prior to initiation of randomized treatment, OR stable on current medication for a minimum of 6 weeks and willing to maintain a stable dose
* Willingness and ability to perform the yoga intervention and to comply with the requirements of the study protocol.
* For women of childbearing potential, willingness to use a reliable form of birth control

Exclusion Criteria:

* Patients unable to understand study procedures and participate in the informed consent process.
* Pregnancy as assessed by pregnancy test at screen or lack of use approved methods birth control for women of childbearing age
* Women who are planning to become pregnant
* Serious medical illness or instability for which hospitalization may be likely within the next year
* Significant current suicidal ideation or suicidal behaviors within the past 6 months (assessed with the Beck Depression Inventory-II \[BDI-II\])
* History of head trauma causing loss of consciousness, or seizure disorder resulting in ongoing cognitive impairment
* Posttraumatic stress disorder, substance use disorder, eating disorder, or organic mental disorder within the past 6 months
* Lifetime history of psychotic disorder, bipolar disorder, or developmental disorder
* Significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview)
* Prior experience with (more than 5 Yoga classes or CBT sessions within the last 3 years) and/or current practice of mindbody techniques (e.g., yoga, meditation, Tai-Chi, etc) or cognitive behavioral therapy (CBT)
* Concomitant therapy for generalized anxiety disorder (GAD) (any therapy)
* Physical conditions that might cause injury from yoga (pregnancy, physical injuries and musculoskeletal problems)
* Cognitive impairment (MOCA\<21)
Effect of Mild Sedation and Analgesia on Radial Artery Cannulation in Novice Residents

The aim of this study is to conduct a prospective, single-center randomized controlled study to investigate the effect of mild midazolam combined with sufentanil on radial artery cannulation in novice operators.

outcome: patients discomfort，visual analogue scale，First-attempt success rate，the success rate of radial artery cannulation within 10 minutes, Complication rate

Eligibility Criteria:
Inclusion Criteria:

* Patients who required arterial cannulation for continuous blood pressure monitoring
* Aged \>20years
* ASA physical status of 1-3
* BMI 18-28kg/m2
* All patients agreed to participate in this study at the time of recruitment and signed an informed consent form.

Exclusion Criteria:

* a positive Allen's test
* infection at the puncture site
* coagulation disorders; arterial diseases (such as Raynaud's disease or thromboangiitis obliterans)
* use of vasoactive drugs within 30 minutes before measurement during the study
* patients with arterial abnormalities and bends; hemorrhagic shock
* arterial atherosclerosis; radial artery puncture within the past 30 days
* chronic use of opioid or benzodiazepine drugs
* and known allergies or adverse reactions to benzodiazepines or opioids.
Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards

Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The investigator wish to examine prospectively whether giving replacement therapy affects mortality, length of hospital stay and overall well-being. In order to replete intracellular levels and replete magnesium stores, magnesium should be given for several months.


Eligibility Criteria:
Inclusion Criteria:

* Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent.

Exclusion Criteria:

* A patient unable to give consent.
* A patient admitted for an elective procedure.
* A patient in critical condition or dying.
* Patients with advanced kidney disease with eGFR\<15ml/min or on dialysis.
* Patients with severe diarrhea, precluding use of magnesium citrate.
* Patients already receiving magnesium supplements.
* Patients with severe malnutrition or life-threatening hypomagnesemia (serum level \<1mg/dL), requiring intravenous and oral replacement of magnesium.
Competitive Accuracy of Radiological Imaging Compared to Liver Biopsy in Patients With Liver Fibrosis

The study "Competitive Accuracy of Radiological Imaging Compared to Liver Biopsy in Patients With Liver Fibrosis" is designed to test the accuracy of non-interventional radiological imaging and compare its results with the "gold standard" liver biopsy. This is prospective non-randomized single patient group study.


Eligibility Criteria:
Inclusion Criteria:

* chronic liver disease
* signed informed consent
* liver biopsy indicated by treating gastroenterologist/infectologist

Exclusion Criteria:

* non-corrected blood coagulation tests
* acute liver disease
* age below 18 years or above 80 years
* disagreement to participate in the study
* pregnancy
Management of Labor in Patients With Previous Cesarian Section

Induction of labor in women desiring TOLAC has long been a topic of controversy. The paucity of published data on mechanical cervical ripening in the setting of TOLAC and term PROM has led us to undertake the present clinical trial.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed to be pregnant with PROM at \>34 weeks. Rupture of membranes will be determine clinically and confirmed by positive Nitrazine test.
* Ruptured membranes have occurred in the last 24 hours prior to inclusion in the study.
* Found to have an unripe cervix in a speculum examination.
* Singleton pregnancy in a vertex presentation well applied to the cervix and absence of significant and regular uterine contractions (3-5/10 Min)
* Previous on cesarian section.
* Willingness to comply with the protocol for the duration of the study.
* Have signed an informed consent.

Exclusion Criteria: Patients having any of the following conditions:

* Any contraindication for the vaginal delivery (i.e. placenta previa, non vertex presentation).
* Regular uterine contractions (3-5/10 min).
* Diagnosis of rupture membranes was made over 24 hours prior the study inclusion.
* Evidence of chorio-amnionitis (T 37.6 celsious Degree with uterine tenderness and maternal or fetal tachycardia or purulent discharge or WBC\>/=20,000)
* Suspected placental abruption or presence of a significant hemorrhage.
* Non-reassuring fetal status (as determined by fetal heart rate monitoring and/or bio-physical profile) necessitating immediate intervention.
International Validation of Two Non-motor Scales in PD (NFS and SPARK)

The goal of this project is to develop the international validation of two new rating scales, the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale, in order to improve the understanding of the extent and severity of non-motor symptoms in Parkinson's disease (PD).

This project is a prospective international multicentre study to validate two new rating scales in different languages: the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale.

The project population consists a minimum of 300 PD patients with and without fluctuations in the participant countries: Spain, Germany, France, Switzerland, Romania and Greece.

The NFS is specifically designed to detect neuropsychiatric fluctuations between off- and on-medication condition in PD. It is composed of 20 items, 10 items measuring the on-neuropsychological symptoms and 10 items for the off-neuropsychological manifestations. The validation of this scale, based on the most frequently experienced symptoms by the patients, would allow a crucial breakthrough in the improvement of management of PD patients.

Shame and embarrassment are poorly recognized by physicians in PD. PD-related shame and embarrassment may emerge from motor and non-motor symptoms, from self-perception of inadequacy due to loss of autonomy and need for help, or from perceived deterioration of body image. The current available scales are not specific for PD. Based on reports of persons affected with PD and a literature review about shame and stigmatization in PD a 25-items self-questionnaire for shame and embarrassment in PD was created. The scale includes 6 different subscales (1. Shame arising from PD symptoms; 2. Shame arising from the increasing physical dependence and need for help induced by PD; 3. Shame arising from the patient's assumption of breaking certain social rules; 4. Shame arising from the deteriorated body image; 5. Consequence of related shame and embarrassment on patients' health-related quality of life; 6. Stigmatization). The validation of this scale will give a tool for physicians and researchers to better understand the impact of PD on patient's quality of life.

Eligibility Criteria:
Inclusion Criteria:

1. Written informed consent;
2. PD, according to the MDS criteria;
3. Age of participants \> 30 and \< 75 years;
4. Being fluent in the language in which the scales are applied.

Exclusion Criteria:

1. Presence of PD dementia (defined as MoCA score \< 24).
Simplifying the World Health Organization (WHO) Protocol for Hand Hygiene

Non-inferiority in terms of reduction of bacterial counts will be investigated when combining the simpler three-step hand hygiene technique for the use of hand rub with a shorter application time of 15 seconds compared to the to the three steps technique with an application time of 30 seconds and the technique consisting in six steps.


Eligibility Criteria:
Inclusion Criteria:

* Adult participants (≥18 years)

Exclusion Criteria:

* skin disorders as determined by a dermatologist
* inability to follow procedures
* insufficient knowledge of the project language
* inability to give informed consent
Clinical, Biochemical and Haemodynamic Effects of Large-volume Paracentesis (LVP) in Inflammatory Situations

This observational study evaluates the clinical, biochemical and haemodynamic effects of large-volume paracentesis (LVP) in 50 patients with and without signs of inflammation

Ascites is one of the common complications in advanced liver cirrhosis. Large-volume paracentesis (LVP) is a widely used symptomatic intervention to remove large amounts of peritoneal fluid. Despite a low rate of interventional-associated complications like fistula or non life-threatening bleeding LVP induces an impairment of circulatory function. The hypothesis is that haemodynamic changes can be detected by non-invasive monitoring and that these haemodynamic changes could be associated to postinterventional organ dysfunction or complications. Additionally the investigators hypothesize that paracentesis-induced circulatory dysfunction could also be associated to present clinical and laboratory signs of inflammation or infection and could influenced by increased viable and non-viable bacterial translocation.

Eligibility Criteria:
Inclusion Criteria:

* Female and male Patients between 18-70 years with liver cirrhosis and ascites
* Indication for paracentesis

Exclusion Criteria:

* Infectious disease in the last 4 weeks
* Active alcohol-consumption or missing data of alcohol use
* Missing inform consent
* Missing speech comprehension
* Neurological or psychiatric disease that compromise consenting
* Hepatic encephalopathy stage III (West-Haven criteria)
* Heart failure NYHA IV
* Renal insufficiency or hepatorenal syndrome
* Atrial fibrillation
* Pacemaker
The Effect of Respiratory on Sports Performance in Archers

Purpose: The physical, physiological, and functional characteristics of archers affect target shooting performance. In our study, we aimed to examine the effect of pulmonary functions and respiratory muscle strength on sports performance in archers.

Methods: Our study included 46 (27 female, 19 male) professional archers registered in archery sports clubs. Sociodemographic and physical characteristics were recorded. Pulmonary function test (PFT), respiratory muscle strength, shooting performance test, Moberg-pickup collection test, Nelson hand reaction test, and Fatigue Severity Scale (FSS) were applied to all participants.


Eligibility Criteria:
Inclusion Criteria:

* Between 18-30 years old,
* Professional archers.

Exclusion Criteria:

* Participants who had COVID-19 (Coronavirus Disease) in the last 2 months,
* Musculoskeletal disorders,
* Orthopedic surgery,
* Smoking history,
* Neurologic and pulmonary diseases.
A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD

The purpose of this study is to investigate the efficacy, safety and tolerability of AD 237 in patients with chronic obstructive pulmonary disease (COPD).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with COPD, with symptoms of cough and chronic sputum production and/or dyspnea.
* Post-bronchodilator FEV1 at no more than 65% and at least 30% of the predicted normal value.
* Pre-bronchodilator FEV1/FVC ratio of less than 70%.
* Current or ex-smokers with a smoking history of at least 10 pack years.

Exclusion Criteria:

* History of asthma, atopy or allergic rhinitis.
* Other serious respiratory or other medical conditions which may interfere with the outcome of the study.
Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma

The present study will be a multicenter, prospective phase II-study investigating safety and efficacy of the combination of auto-allo tandem stem cell transplantation in patients with multiple myeloma and age of \>_60 years, followed by maintenance therapy with low-dose Thalidomide and Donor Lymphocyte Infusions.


Eligibility Criteria:
Inclusion Criteria:

* Multiple Myeloma Stage II or III acc. to Salmon and Durie
* Patient's age 18-60 years
* Patient's written informed consent
* Women and men capable of reproduction must agree to use adequate contraceptive measures (condom, IUD, oral contraceptives) until three months after termination of treatment
* a maximum of eight chemotherapy cycles prior to registration (CR/ PR/ MR/ or PD)

Exclusion Criteria:

* More than eight chemotherapy cycles prior to registration
* severe irreversible renal, hepatic, pulmonary or cardiac disease, such as

  * total bilirubin, SGPT or SGOT \> 3 times upper the normal level
  * Left ventricular ejection fraction \< 30 %
  * Creatinine Clearance \< 30 ml/min
  * DLCO \< 35 % and/or receiving supplementary continuous oxygen
* Positive serology for HIV
* Pregnant or lactating women
* Participation in another trial at the time of registration
* Preceding autologous stem cell transplantation
* age \> 61 years
EPID Multiple Sclerosis Pregnancy Study

Multiple Sclerosis (MS) is the most common chronic neurologic disability in young adult females in their childbearing ages. Little evidence is available regarding the association between exposure to IFN-beta (β) products and adverse pregnancy outcomes. Therefore the four marketing holders of IFN-β are conducting a European-wide IFN-β pregnancy registry. Additionally, the Committee for Medicinal Products for Human Use (CHMP) has requested a study to enable identification of pregnancy outcomes in the MS population unexposed to IFN-β products for comparison with the ongoing European IFN-β Pregnancy Registry.

Information will be obtained from the Drugs and Pregnancy Project database (DPP - FIN) and the Medical Birth Register (MBR - SWE, NOR). The Finnish DPP and Norwegian MBR include information on all stillbirths of foetuses with a birth weight of at least 500 g or with a gestational age of at least 22+0 Gestational Week (GW). The Swedish MBR includes data on stillbirths after 28 GW

The estimated number of pregnancies in MS patients needed is 1671, encompassing data from:

i) FIN: 1 January 1996 - 31 December 2014; ii) SWE: 1 July 2005 - 31 December 2014; iii) NOR: 1 January 2004 - 31 December 2014.

Eligibility Criteria:
Inclusion Criteria:

* Women who have had a pregnancy with a recorded outcome consisting of an induced abortion, spontaneous abortion, ectopic pregnancy, or birth during the study period in FIN, SWE or NOR with the event being documented in the relevant databases.
Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone

Abstract: Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder characterized by inflammation, blistering, and scarring and predominantly occurring at mucous membranes. Successful treatment can be challenging, and uncontrolled disease may result in significant morbidity with scarring of the conjunctiva and oropharynx leading to blindness and dysphagia. Therefore successful treatment is a must to improve patient quality of life.

Aim of work: to evaluate clinically the effectiveness of systemic large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP cases.

Materials and method: 10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II). The lesion size and pain score will be assessed before treatment and during treatment in stage I and stage II. These data will be tabulated and statistically analyzed

Before starting any treatment the size of the lesion will be measured and pain score will be evaluated. then patient were treated using large dose of prednisone 60mg daily plus intra-lesional injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) at this stage the patients pain would be evaluated and lesion size would be measured .

as no further improvement is gained, the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II) at this stage the patients pain would be evaluated and lesion size would be measured. then the data will be tabulated and statistically analyzed regarding pain score and lesion size

Eligibility Criteria:
Inclusion Criteria:

patients with age references patients confirmed from dermatology department that they had mucous membrane(MMP) pemphigoid- patients are not allergic o to the drugs being used for the treatment

Exclusion Criteria:

patients below or above age reference used in the study patients with other oral lesions not being confirmed as MMP patients with systemic diseases preventing using of the drugs

-
Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain from Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Feasibility Study

To learn if peripheral nerve stimulation (PNS) can help to improve pain in participants with CIPN.

Primary objective:

To assess Pain intensity (NRS) scores in chemotherapy induced peripheral neuropathy (CIPN) participants before and after use of peripheral nerve stimulation (PNS).

Secondary objectives:

To assess changes in quantitative sensory testing (QST), gait testing, and skin punch biopsy to compare the integrity of Meissner's corpuscles (MC), pain disability using the Oswestry Disability Index (ODI), pain interference using the Brief Pain Inventory (BPI), and Patient Global Impression of Change (PGIC) in CIPN patients before and after use of PNS.

Eligibility Criteria:
Inclusion Criteria:

* Participants diagnosed with chronic (≥90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation) of the lower extremity, seen at Pain Management Center at MD Anderson Cancer Center
* Participants reports baseline pain ≥ 4 (0-10 scale, NRS)
* Participants between ages 18-85 years old
* Participants who have completed chemotherapy within the previous year at the time of enrollment

Exclusion Criteria:

* Participants with cognitive dysfunction
* Participants with recent history (\<6 months) of drug or alcohol abuse
* Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection
* Participants with allergies to local anesthesia, steroids, or adhesives
* Participants with conditions that conflict with the SPRINT PNS System Indications for Use, including Contraindications and Warnings.